全文获取类型
收费全文 | 764篇 |
免费 | 58篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 59篇 |
妇产科学 | 21篇 |
基础医学 | 120篇 |
口腔科学 | 37篇 |
临床医学 | 111篇 |
内科学 | 195篇 |
皮肤病学 | 11篇 |
神经病学 | 22篇 |
特种医学 | 117篇 |
外科学 | 42篇 |
综合类 | 12篇 |
预防医学 | 30篇 |
眼科学 | 3篇 |
药学 | 53篇 |
1篇 | |
肿瘤学 | 32篇 |
出版年
2023年 | 5篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 6篇 |
2018年 | 11篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 24篇 |
2014年 | 24篇 |
2013年 | 36篇 |
2012年 | 16篇 |
2011年 | 26篇 |
2010年 | 27篇 |
2009年 | 29篇 |
2008年 | 20篇 |
2007年 | 51篇 |
2006年 | 26篇 |
2005年 | 20篇 |
2004年 | 11篇 |
2003年 | 11篇 |
2002年 | 18篇 |
2001年 | 10篇 |
2000年 | 10篇 |
1999年 | 13篇 |
1998年 | 45篇 |
1997年 | 53篇 |
1996年 | 55篇 |
1995年 | 45篇 |
1994年 | 30篇 |
1993年 | 30篇 |
1992年 | 2篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 14篇 |
1988年 | 24篇 |
1987年 | 19篇 |
1986年 | 14篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1972年 | 2篇 |
1960年 | 1篇 |
排序方式: 共有868条查询结果,搜索用时 31 毫秒
71.
72.
胶体磷酸铬^32P关节腔内注射改善佐剂型关节炎大鼠的相关指标 总被引:1,自引:0,他引:1
目的:观察胶体磷酸铬32P关节腔内注射治疗大鼠佐剂型关节炎的效果。方法:实验于2006-07/09在南京市第一医院动物实验室完成。选择6~8周龄清洁级SD雌性大鼠30只,按随机数字表法分为3组,正常对照组、模型组、胶体磷酸铬32P治疗组,每组10只。大鼠左足跖皮内注射完全弗氏佐剂0.1mL免疫法制备佐剂型关节炎模型。胶体磷酸铬32P治疗组于造模后10d左踝关节腔内注射37GBq/L胶体磷酸铬32P0.02mL,即0.74MBq,正常对照组和模型组分别给予等量生理盐水左踝关节腔内注射。①每2周观察1次大鼠左踝关节左右径宽度。②关节炎指数评定采用关节炎评分法(0~4分),分数越高,症状越重。③于用药后2,4,6周采用99Tcm-MDP显像感兴趣区分析法计算大鼠左踝关节区和右胫腓骨的放射性计数比。④于用药后4,6周测定血清肿瘤坏死因子和白细胞介素1β水平。⑤于用药后4,6周观察大鼠滑膜组织和软骨组织病理学改变。结果:纳入大鼠30只,均进入结果分析。①用药后2周模型组大鼠左踝关节左右径宽度大于正常对照组[分别为(7.82±0.36),(5.89±0.35)mm],差异有显著性意义(t=12.16,P<0.001),胶体磷酸铬32P治疗组大鼠左踝关节左右径宽度大于模型组,差异无显著性意义(P>0.05)。用药后6周胶体磷酸铬32P治疗组大鼠左踝关节左右径宽度小于模型组[分别为(6.87±0.27),(7.25±0.26)mm],差异有显著性意义(t=2.87,P<0.05)。②用药后2周和4周胶体磷酸铬32P治疗组大鼠关节炎指数高于模型组,用药后6周胶体磷酸铬32P治疗组大鼠关节炎指数低于模型组,两组间差异均无显著性意义(P>0.05)。③用药后2周模型组大鼠感兴趣区放射性计数比高于正常对照组(分别为2.05±0.20,1.46±0.15),差异有显著性意义(t=7.46,P<0.001)。用药后6周胶体磷酸铬32P治疗组大鼠感兴趣区放射性计数比低于模型组(分别为1.52±0.18,1.78±0.24),差异有显著性意义(t=2.45,P<0.05)。④用药后4,6周模型组大鼠血清肿瘤坏死因子和白细胞介素1β水平高于正常对照组,差异有显著性意义[用药后4周分别为(2.039±0.344),(1.115±0.192)μg/L;(0.305±0.034),(0.192±0.041)μg/L,t=7.42,6.71,P<0.001。用药后6周分别为(1.694±0.305),(1.126±0.256)μg/L;(0.259±0.027),(0.191±0.019)μg/L,t=4.03,5.83,P<0.01,0.001]。用药后4,6周胶体磷酸铬32P治疗组在血清肿瘤坏死因子和白细胞介素1β水平与模型组比较,差异无显著性意义(P>0.05)。⑤用药后4周胶体磷酸铬32P治疗组和模型组滑膜组织增生和炎症细胞浸润均较明显;用药后6周胶体磷酸铬32P治疗组与正常对照组比较仍有滑膜组织增生和炎症细胞浸润,与模型组比较滑膜组织增生程度明显减轻,而炎症细胞浸润程度稍轻。用药后6周胶体磷酸铬32P治疗组大鼠左踝关节的软骨组织未见有异常改变。结论:胶体磷酸铬32P关节腔注射可减轻完全弗氏佐剂免疫大鼠受注射关节的滑膜增生程度,改善关节肿胀症状,疗效肯定。 相似文献
73.
Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden 总被引:7,自引:0,他引:7
Jackson LM; O'Gorman PJ; O'Connell J; Cronin CC; Cotter KP; Shanahan F 《QJM : monthly journal of the Association of Physicians》1997,90(3):183-188
Patients with inflammatory bowel disease have an increased frequency of
thromboembolism, and microvascular thrombosis has been proposed as a
contributory pathogenic factor. The mechanism of enhanced procoagulant
activity is not understood. We examined the clinical setting of
thromboembolic events in 52 patients with Crohn's disease or ulcerative
colitis, and assessed the procoagulant laboratory profile, including Factor
V Leiden, in a subset of 20 patients to identify procoagulant risk factors.
Patients who developed thrombosis tended to be young; 60% of thrombotic
events occurred in patients under 50 years. Multiple thromboembolic
episodes occurred in 13% and unusual sites of thrombosis (e.g.
intracardiac, cerebral, inominate veins) in 11%. No risk factor was
identifiable in 52% of cases and two-thirds of thromboses occurred in an
out-patient setting. The mortality rate was 8%. Evidence for inflammatory
disease activity was found in only 45% of patients with ulcerative colitis
at the time of the thromboembolic event, in contrast to 89% of those with
Crohn's disease. Assays for specific coagulation defects were negative in
all cases tested (protein S, C were normal in 17/17; anti-thrombin III,
anti-phospholipid antibodies and activated protein C resistance were
negative in 20/20, and only 1/20 patients was found to be heterozygous for
Factor V leiden. Thrombosis in inflammatory bowel disease is important
because it occurs in a young population, often in unusual sites, and has a
high mortality. The development of thrombosis is related to active
inflammatory disease in most patients with Crohn's disease but apparently
not in those with ulcerative colitis. Since approximately half of the
patients had no other identifiable risk factor, there remains a substantial
group of patients with IBD who develop thrombosis for unknown reasons.
相似文献
74.
Long‐term outcome and quality of life in patients with total colonic aganglionosis in the Netherlands 下载免费PDF全文
75.
Timothy J. Kidd Kay A. Ramsay Honghua Hu Peter T. P. Bye Mark R. Elkins Keith Grimwood Colin Harbour Guy B. Marks Michael D. Nissen Philip J. Robinson Barbara R. Rose Theo P. Sloots Claire E. Wainwright Scott C. Bell and the ACPinCF Investigators? 《Journal of clinical microbiology》2009,47(5):1503-1509
Pseudomonas aeruginosa is an important cause of pulmonary infection in cystic fibrosis (CF). Its correct identification ensures effective patient management and infection control strategies. However, little is known about how often CF sputum isolates are falsely identified as P. aeruginosa. We used P. aeruginosa-specific duplex real-time PCR assays to determine if 2,267 P. aeruginosa sputum isolates from 561 CF patients were correctly identified by 17 Australian clinical microbiology laboratories. Misidentified isolates underwent further phenotypic tests, amplified rRNA gene restriction analysis, and partial 16S rRNA gene sequence analysis. Participating laboratories were surveyed on how they identified P. aeruginosa from CF sputum. Overall, 2,214 (97.7%) isolates from 531 (94.7%) CF patients were correctly identified as P. aeruginosa. Further testing with the API 20NE kit correctly identified only 34 (59%) of the misidentified isolates. Twelve (40%) patients had previously grown the misidentified species in their sputum. Achromobacter xylosoxidans (n = 21), Stenotrophomonas maltophilia (n = 15), and Inquilinus limosus (n = 4) were the species most commonly misidentified as P. aeruginosa. Overall, there were very low rates of P. aeruginosa misidentification among isolates from a broad cross section of Australian CF patients. Additional improvements are possible by undertaking a culture history review, noting colonial morphology, and performing stringent oxidase, DNase, and colistin susceptibility testing for all presumptive P. aeruginosa isolates. Isolates exhibiting atypical phenotypic features should be evaluated further by additional phenotypic or genotypic identification techniques.The accurate identification of Pseudomonas aeruginosa is a critical component of cystic fibrosis (CF) patient management. Once established within CF lungs, P. aeruginosa is rarely eradicated, leading to increased treatment requirements and an accelerated decline in pulmonary function, quality of life, and life expectancy (10, 13, 27). Emerging evidence indicates that aggressive antipseudomonal therapy at the time of initial acquisition may eliminate P. aeruginosa, preventing the development of chronic infection for months or even years (37). Similarly, separating patients with P. aeruginosa from other CF patients may reduce the spread of multiple-antibiotic-resistant strains capable of person-to-person transmission (16). Such strategies are contingent upon the early and correct identification of these organisms (30).While there is much emphasis on misidentifying P. aeruginosa as another species (39), less attention is paid to falsely identifying other species as P. aeruginosa. Nevertheless, accurate identification of P. aeruginosa is important, as this may avoid prolonged and sometimes unnecessary antibiotic treatments, which could select for other antibiotic-resistant pathogens (6). Similarly, in CF clinics where cohort isolation is practiced as an infection control measure, false identification could mean exposure of the CF patient to potentially transmissible bacteria (2, 17, 28, 33).While most clinical strains of P. aeruginosa are easily identified, respiratory isolates from patients with CF can present a taxonomic challenge (15, 24). Phenotypic identification of P. aeruginosa from patients with CF is often complicated by slow growth, auxotrophic metabolic activity, loss of pigment production, multiple antibiotic resistance, atypical colonial morphology, and development of mucoid exopolysaccharide (14, 25). Commercial identification platforms are also considered unreliable (18, 21, 39). Moreover, CF respiratory secretions may contain other nonfermenting gram-negative bacilli, such as Achromobacter, Stenotrophomonas, and Burkholderia species, which can further impede the identification of P. aeruginosa (29, 32, 35, 39).Although several molecular strategies have been developed recently (1, 35, 39), most clinical microbiology laboratories still identify P. aeruginosa by traditional phenotypic techniques. However, there are few published data describing the frequency at which bacterial species in CF sputum are falsely identified as P. aeruginosa by phenotypic methods. In this study, we used P. aeruginosa-specific duplex real-time (PAduplex) PCR assays, phenotypic analysis, amplified rRNA gene restriction analysis (ARDRA), and partial 16S rRNA gene sequence analysis to assess the rate and extent of misidentification of P. aeruginosa isolates in CF sputum by Australian clinical microbiology laboratories. 相似文献
76.
Patrick W Dielissen Ben JAM Bottema Petra Verdonk Toine LM Lagro-Janssen 《BMC medical education》2009,9(1):58
Background
We recently set standards for gender-specific medicine training as an integrated part of the GP training curriculum. This paper describes the programme and evaluation of this training. 相似文献77.
78.
Aníbal E Carbajo Carolina Vera Paula LM González 《International journal of health geographics》2009,8(1):44-10
Background
Oligoryzomys longicaudatus (colilargo) is the rodent responsible for hantavirus pulmonary syndrome (HPS) in Argentine Patagonia. In past decades (1967–1998), trends of precipitation reduction and surface air temperature increase have been observed in western Patagonia. We explore how the potential distribution of the hantavirus reservoir would change under different climate change scenarios based on the observed trends. 相似文献79.
Morschhauser F Zinzani PL Burgess M Sloots L Bouafia F Dumontet C 《Leukemia & lymphoma》2007,48(4):708-715
A phase I/II trial was performed to investigate the safety and tolerance of zosuquidar.3HCL, a potent inhibitor of P-glycoprotein (P-gp), when administered orally alone and in combination with the CHOP regimen in patients with untreated non-Hodgkin's lymphoma and to determine whether zosuquidar.3HCL affects pharmacokinetics of doxorubicin and vincristine. Doses of CHOP remained constant and the doses of zosuquidar.3HCL were increased from 200 to 500 mg per dose. A total of 15 patients were treated at three dose levels. A target dose providing peak and trough levels compatible with prolonged modulation of P-gp function was obtained in patients receiving three doses of 500 mg of zosuquidar.3HCL p.o. At this dose level, toxicity was minimal and no enhancement of CHOP-related toxicity was observed. Zosuquidar.3HCL did not significantly affect the pharmacokinetics of doxorubicin and had moderate effects on the pharmacokinetics of vincristine. Zosuquidar.3HCL can be safely administered with CHOP therapy using a 24-h schedule. 相似文献
80.
Goire N Nissen MD LeCornec GM Sloots TP Whiley DM 《Diagnostic microbiology and infectious disease》2008,61(1):6-12
Cross-reactions of gonococcal nucleic acid amplification tests (NAATs) with commensal Neisseria strains are well documented. Recent data now indicate that sequence-related false-negative results can occur in gonococcal NAATs, whereby target sequences either are absent or contain several mutations. In this study, a duplex Neisseria gonorrhoeae real-time polymerase chain reaction (PCR) (NGduplex) assay targeting the gonococcal porA pseudogene and multicopy opa genes was developed. The NGduplex was evaluated by testing 596 clinical specimens, including 292 urogenital specimens and 304 throat swab specimens. The results were compared with those obtained using a consensus reference standard comprising 3 monoplex real-time PCR assays. The results show that the NGduplex assay is highly suitable for routine screening for gonorrhea, providing an overall clinical sensitivity and specificity of 100% and 99.3%, respectively, for both urogenital and throat swab specimens. In addition, the 2-target system of the NGduplex assay decreases the potential for sequence-related false-negative results and can provide simultaneous confirmation of positive results. 相似文献